Teijin Pharma Limited - Product Pipeline Review - 2014

Published: Dec, 2014 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Teijin Pharma Limited - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Teijin Pharma Limited - Product Pipeline Review - 2014', provides an overview of the Teijin Pharma Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Teijin Pharma Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Teijin Pharma Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Teijin Pharma Limited's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Teijin Pharma Limited's pipeline products

Reasons to buy

- Evaluate Teijin Pharma Limited's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Teijin Pharma Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Teijin Pharma Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Teijin Pharma Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Teijin Pharma Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Teijin Pharma Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Teijin Pharma Limited Snapshot 5
Teijin Pharma Limited Overview 5
Key Information 5
Key Facts 5
Teijin Pharma Limited - Research and Development Overview 6
Key Therapeutic Areas 6
Teijin Pharma Limited - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Teijin Pharma Limited - Pipeline Products Glance 14
Teijin Pharma Limited - Late Stage Pipeline Products 14
Phase III Products/Combination Treatment Modalities 14
Teijin Pharma Limited - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Teijin Pharma Limited - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Discovery Products/Combination Treatment Modalities 18
Teijin Pharma Limited - Drug Profiles 19
febuxostat 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
immune globulin (human) 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
abaloparatide 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
KTP-001 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
lanreotide acetate 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
ADC-3680 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ambroxol 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
TMG-123 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules to Target ROR gamma for Autoimmune Diseases 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Teijin Pharma Limited - Pipeline Analysis 34
Teijin Pharma Limited - Pipeline Products by Target 34
Teijin Pharma Limited - Pipeline Products by Route of Administration 36
Teijin Pharma Limited - Pipeline Products by Molecule Type 37
Teijin Pharma Limited - Pipeline Products by Mechanism of Action 38
Teijin Pharma Limited - Recent Pipeline Updates 39
Teijin Pharma Limited - Dormant Projects 43
Teijin Pharma Limited - Discontinued Pipeline Products 44
Discontinued Pipeline Product Profiles 44
NTC-801 44
taspoglutide 44
Teijin Pharma Limited - Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48

List of Tables
Teijin Pharma Limited, Key Information 5
Teijin Pharma Limited, Key Facts 5
Teijin Pharma Limited - Pipeline by Indication, 2014 7
Teijin Pharma Limited - Pipeline by Stage of Development, 2014 8
Teijin Pharma Limited - Monotherapy Products in Pipeline, 2014 9
Teijin Pharma Limited - Partnered Products in Pipeline, 2014 10
Teijin Pharma Limited - Partnered Products/ Combination Treatment Modalities, 2014 11
Teijin Pharma Limited - Out-Licensed Products in Pipeline, 2014 12
Teijin Pharma Limited - Out-Licensed Products/ Combination Treatment Modalities, 2014 13
Teijin Pharma Limited - Phase III, 2014 14
Teijin Pharma Limited - Phase II, 2014 15
Teijin Pharma Limited - Phase I, 2014 16
Teijin Pharma Limited - Preclinical, 2014 17
Teijin Pharma Limited - Discovery, 2014 18
Teijin Pharma Limited - Pipeline by Target, 2014 35
Teijin Pharma Limited - Pipeline by Route of Administration, 2014 36
Teijin Pharma Limited - Pipeline by Molecule Type, 2014 37
Teijin Pharma Limited - Pipeline Products by Mechanism of Action, 2014 38
Teijin Pharma Limited - Recent Pipeline Updates, 2014 39
Teijin Pharma Limited - Dormant Developmental Projects,2014 43
Teijin Pharma Limited - Discontinued Pipeline Products, 2014 44
Teijin Pharma Limited, Other Locations 45
Teijin Pharma Limited, Subsidiaries 46